Business
New Study Shows Impact of Ambry Genetics’ Patient for Life™ Program on Rare Disease Diagnosis
ALISO VIEJO, Calif., May 27, 2025--New study published in Genetics in Medicine reveals transformative impact of Ambry's Patient for Life reanalysis program.
About this update from Tempus Ai, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3000,"height":600,"url":"https://media.zenfs.com/en/business-wire.com/b0906fe0f94e505f4e6cf83042c2144b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I3Ycb7byowdoFMb0boUn1Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b0906fe0f94e505f4e6cf83042c2144b","width":960,"height":192},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Njb26txzlKFBOeIC7wAH9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00ODA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/b0906fe0f94e505f4e6cf83042c2144b","width":1200,"height":240}},"lazy":false},{"type":"text","content":"Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes","length":100,"tagName":"p","attribs":{}},{"type":"text","content":"ALISO VIEJO, Calif., May 27, 2025--(BUSINESS WIRE)--Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), and a leader in clinical genomic testing, today announced the publication of a study in Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG). The study reveals the potentially transformative impact of Ambry Genetics’ Patient for Life™ program, which systematically reanalyzes data from the company’s database of exome test results. By reclassifying genetic variants based on newly discovered gene-disease associations and emerging evidence supporting variant pathogenicity, the program may offer renewed hope to patients and families facing undiagnosed rare diseases. Over the study period, 5% of initially negative or uninformative case results that received proactive reanalysis led to a diagnosis.","length":886,"tagName":"p"},{"type":"text","content":"The term "rare disease" comprises more than 7,000 diseases, each affecting fewer than 200,000 Americans, collectively impacting 25 million to 30 million individuals.1 Exome sequencing tests – which examine the coding regions of genomic DNA – are typically indicated for evaluating children with congenital birth defects, intellectual disability, and neurodevelopmental disorders such as autism spectrum disorder and epilepsy.2 Ambry Genetics was the first commercial laboratory to begin offering clinical ...